Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Subscribe To Our Newsletter & Stay Updated
